Effects of Radiofrequency Ablation (RFA) in combination with Sorafenib in a 2-Tumor Rat Model of Hepatocellular Carcinoma
C Hora, JC Mertens, B Saar, J Kettenbach, M Ledermann, S Mertens, JF Dufour, A Geier · Zeitschrift für Gastroenterologie · 2011 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Radiofrequency ablation (RFA) is a established therapy for hepatocellular carcinoma (HCC). Multitkinase inhibitor sorafenib prolongs survival in advanced HCC. We examined effects of RFA combined with sorafenib in a two-tumor rat model of HCC. Methods: 1mm cubes of Morris Hepatoma cells (MH) were were implanted into the right and left liver lobe of syngeneic ACI rats in four treatment groups. We administered sorafenib (7.5mg/kg/d) or vehicle p.o., starting d 12 after tumor implantation. RFA of the left lobe tumor or sham operation was performed on d 15. Group 1 received vehicle and a sham operation. Group 2…
